http://www.sarepta.com/ 2025-12-17T16:48:09+00:00 daily 1.0 http://www.sarepta.com/newsroom/how-sarepta-infused-its-corporate-brand-urgency-and-optimism-behalf-patients 2023-04-26T16:48:43+00:00 0.5 http://www.sarepta.com/newsroom/advocacy-community-unites-support-families 2023-04-26T16:48:30+00:00 0.5 http://www.sarepta.com/newsroom/expanding-access-newborn-screening-those-rare-diseases 2023-04-26T16:48:05+00:00 0.5 http://www.sarepta.com/newsroom/welcome-gt-faq 2022-12-19T15:03:43+00:00 0.5 http://www.sarepta.com/newsroom/measurements-used-clinical-trials-duchenne-muscular-dystrophy-overview 2025-11-04T20:17:16+00:00 0.5 http://www.sarepta.com/newsroom/seroprevalence-what-patients-should-know-about-pre-existing-antibodies-gene-therapy 2022-12-19T15:05:39+00:00 0.5 http://www.sarepta.com/newsroom/patient-registries-catalyst-developing-new-therapies-rare-diseases 2022-12-19T15:05:25+00:00 0.5 http://www.sarepta.com/newsroom/conversation-cfo-ian-estepan-recipient-2022-cfo-year-award-boston-business-journal 2023-04-26T16:46:32+00:00 0.5 http://www.sarepta.com/newsroom/whatd-you-do-summer-our-summer-interns-share-lessons-learned 2022-12-19T15:02:14+00:00 0.5 http://www.sarepta.com/newsroom/understanding-external-controls-and-their-importance-clinical-trials-rare-diseases 2026-01-27T19:13:52+00:00 0.5 http://www.sarepta.com/newsroom/dragging-tomorrow-today-meet-rachael-potter-phd 2022-12-19T15:02:57+00:00 0.5 http://www.sarepta.com/newsroom/ensuring-safety-clinical-trial-participants-meet-eddie-darton-md 2025-11-25T17:53:31+00:00 0.5 http://www.sarepta.com/newsroom/creating-pathways-lgmd-genetic-diagnosis-spotlight-lgmd-grant-award-recipient 2025-03-19T15:44:33+00:00 0.5 http://www.sarepta.com/newsroom/passion-patients-influential-mentor-and-change-plans-meet-danielle-griffin 2024-09-09T17:32:20+00:00 0.5 http://www.sarepta.com/newsroom/why-are-steroids-used-gene-therapy-neuromuscular-disease 2023-05-25T22:09:54+00:00 0.5 http://www.sarepta.com/newsroom/seeing-hope-genetic-medicines-frontier-meet-stefanie-mason-md 2023-05-09T14:46:50+00:00 0.5 http://www.sarepta.com/newsroom/whats-dose-gene-therapy-dosing-explained-video 2023-07-10T15:58:06+00:00 0.5 http://www.sarepta.com/newsroom/tale-two-interns-meet-kate-katherine-rare-disease-advocates-and-members-sareptas-patient 2023-07-25T21:55:04+00:00 0.5 http://www.sarepta.com/newsroom/guardians-last-mile-ensuring-smooth-delivery-and-seamless-patient-experience 2023-09-14T13:25:51+00:00 0.5 http://www.sarepta.com/newsroom/when-time-muscle-one-dad-shares-his-story-advocate-duchenne-newborn-screening 2024-03-13T20:43:53+00:00 0.5 http://www.sarepta.com/newsroom/continuing-family-legacy-meet-sarepta-colleague-and-duchenne-advocate-shawn-marlow 2023-10-02T19:18:40+00:00 0.5 http://www.sarepta.com/newsroom/awards-recognitions-sarepta-recognized-innovation-and-industry-leadership 2025-04-26T18:27:13+00:00 0.5 http://www.sarepta.com/newsroom/wearable-devices-and-future-rare-disease-clinical-trials-landrys-story 2026-01-09T15:32:08+00:00 0.5 http://www.sarepta.com/newsroom/navy-veteran-lifelong-learner-dedicated-duchenne-nurse-educator-meet-john-crane 2024-05-06T14:34:24+00:00 0.5 http://www.sarepta.com/newsroom/roots-innovation-science-fairs-leading-edge-precision-genetic-medicine 2024-12-02T22:02:03+00:00 0.5 http://www.sarepta.com/newsroom/video-scholarship-recipients-and-twins-austin-and-connor-travel-route-79-together 2025-05-19T20:01:03+00:00 0.5 http://www.sarepta.com/newsroom/leading-science-grounded-patient-impact-meet-james-richardson-md 2025-07-07T15:23:49+00:00 0.5 http://www.sarepta.com/newsroom/portrait-life-duchenne-kasner-familys-story 2026-01-09T15:30:45+00:00 0.5 http://www.sarepta.com/disease-areas 2025-10-30T19:48:18+00:00 0.5 http://www.sarepta.com/science 2025-10-30T19:56:07+00:00 0.5 http://www.sarepta.com/products-pipeline 2025-10-30T20:12:14+00:00 0.5 http://www.sarepta.com/about-us 2025-10-30T20:49:28+00:00 0.5 http://www.sarepta.com/join-us 2026-02-21T00:39:01+00:00 0.5 http://www.sarepta.com/newsroom 2025-10-30T21:23:42+00:00 0.5 http://www.sarepta.com/sareptassist 2023-07-18T14:22:59+00:00 0.5 http://www.sarepta.com/es/sareptassist 2023-07-18T14:22:59+00:00 0.5 http://www.sarepta.com/node/36 2025-12-17T16:48:09+00:00 0.5 http://www.sarepta.com/testing-three-column-cards 2022-07-26T12:16:36+00:00 0.5 http://www.sarepta.com/about-us/patient-affairs 2026-03-25T12:30:56+00:00 0.5 http://www.sarepta.com/disease-areas/duchenne-muscular-dystrophy 2025-10-30T19:51:22+00:00 0.5 http://www.sarepta.com/disease-areas/limb-girdle-muscular-dystrophy 2025-10-30T19:53:36+00:00 0.5 http://www.sarepta.com/science/gene-therapy 2025-10-30T20:04:23+00:00 0.5 http://www.sarepta.com/science/manufacturing 2023-06-27T13:34:32+00:00 0.5 http://www.sarepta.com/science/strategic-partners 2025-10-30T20:08:50+00:00 0.5 http://www.sarepta.com/science/rna-platform 2025-03-28T16:24:52+00:00 0.5 http://www.sarepta.com/products-pipeline/products 2025-07-30T14:08:31+00:00 0.5 http://www.sarepta.com/products-pipeline/clinical-trials 2025-11-04T17:13:18+00:00 0.5 http://www.sarepta.com/products-pipeline/treatment-access 2025-02-04T18:02:02+00:00 0.5 http://www.sarepta.com/about-us/leadership 2026-02-04T20:38:39+00:00 0.5 http://www.sarepta.com/about-us/contact-us 2021-09-15T19:16:07+00:00 0.5 http://www.sarepta.com/terms-use 2024-01-25T20:19:13+00:00 0.5 http://www.sarepta.com/products-pipeline/pipeline 2026-01-30T23:00:49+00:00 0.5 http://www.sarepta.com/about-us/grants-giving 2025-11-17T19:09:58+00:00 0.5 http://www.sarepta.com/404 2020-01-07T15:47:26+00:00 0.5 http://www.sarepta.com/feedback 2020-05-22T15:07:26+00:00 0.5 http://www.sarepta.com/about-us/global-locations 2022-06-07T13:24:48+00:00 0.5 http://www.sarepta.com/app-terms 2020-01-14T13:01:13+00:00 0.5 http://www.sarepta.com/thank-you 2020-01-14T13:03:22+00:00 0.5 http://www.sarepta.com/community-guidelines 2023-02-07T15:25:00+00:00 0.5 http://www.sarepta.com/upload 2020-01-14T13:06:52+00:00 0.5 http://www.sarepta.com/events 2020-01-14T13:57:04+00:00 0.5 http://www.sarepta.com/es/evento 2020-01-14T13:57:04+00:00 0.5 http://www.sarepta.com/peer 2020-01-14T17:59:15+00:00 0.5 http://www.sarepta.com/peer-confirmation 2020-03-09T15:41:42+00:00 0.5 http://www.sarepta.com/about-us/grants-giving/route79 2026-03-04T21:32:23+00:00 0.5 http://www.sarepta.com/terms-embed 2021-03-10T22:00:53+00:00 0.5 http://www.sarepta.com/privacy-embed 2021-03-10T21:59:37+00:00 0.5 http://www.sarepta.com/privacy-policy 2024-01-25T20:16:58+00:00 0.5 http://www.sarepta.com/community-update-covid-19 2020-12-18T16:55:16+00:00 0.5 http://www.sarepta.com/sareptas-response-covid-19 2020-04-01T16:41:42+00:00 0.5 http://www.sarepta.com/about-us/corporate-responsibility 2025-10-30T21:11:36+00:00 0.5 http://www.sarepta.com/eu-us-swiss-us-and-uk-extension-eu-us-data-privacy-framework-privacy-policy 2024-08-13T16:25:54+00:00 0.5 http://www.sarepta.com/rarelessons 2021-02-01T15:14:26+00:00 0.5 http://www.sarepta.com/sareptassist-virtual-event 2020-09-17T16:27:22+00:00 0.5 http://www.sarepta.com/recruiting-fraud 2020-12-07T19:08:55+00:00 0.5 http://www.sarepta.com/GTFAQ 2021-04-26T15:54:26+00:00 0.5 http://www.sarepta.com/community-bulletin-momentum-study-srp-5051-201-update 2022-01-05T15:02:41+00:00 0.5 http://www.sarepta.com/community-bulletin-covid-19-vaccination-and-gene-therapy 2022-01-05T16:32:12+00:00 0.5 http://www.sarepta.com/community-bulletin-srp-9001-clinical-trial-updates 2022-01-05T16:32:56+00:00 0.5 http://www.sarepta.com/community-bulletin-srp-9001-study-103-clinical-trial-update 2022-01-05T16:37:01+00:00 0.5 http://www.sarepta.com/community-bulletin-limb-girdle-facebook-live-event 2022-01-05T16:40:26+00:00 0.5 http://www.sarepta.com/community-bulletin-embark-study-srp-9001-301-enrollment-update 2022-09-13T13:06:39+00:00 0.5 http://www.sarepta.com/community-letter-q1-update-lgmd-programs-development 2022-03-03T15:46:34+00:00 0.5 http://www.sarepta.com/addressing-your-questions-about-covid-19-vaccination-and-gene-therapy 2022-03-23T14:19:44+00:00 0.5 http://www.sarepta.com/community-bulletin-lgmd-2br2-community 2022-05-02T17:00:10+00:00 0.5 http://www.sarepta.com/lgmd-grant-award-program 2025-07-01T14:27:35+00:00 0.5 http://www.sarepta.com/community-bulletin-sarepta-duchenne-pipeline 2022-06-09T00:17:53+00:00 0.5 http://www.sarepta.com/community-letter-momentum-trial 2022-09-06T13:50:19+00:00 0.5 http://www.sarepta.com/community-bulletin-intent-submit-accelerated-approval-biologics-license-application-srp-9001 2022-07-29T11:27:48+00:00 0.5 http://www.sarepta.com/community-bulletin-bla-accepted-filing-priority-review 2022-11-28T16:47:03+00:00 0.5 http://www.sarepta.com/community-letter-community-update-lgmd-programs-development 2023-02-17T13:56:37+00:00 0.5 http://www.sarepta.com/notice-cookies 2023-03-14T14:32:41+00:00 0.5 http://www.sarepta.com/community-letter-srp-9001-advisory-committee-meeting-will-be-held 2023-03-16T20:27:55+00:00 0.5 http://www.sarepta.com/community-letter-srp-9001-advisory-committee-date-announced 2023-04-10T13:40:12+00:00 0.5 http://www.sarepta.com/community-letter-srp-9001-update-regulatory-review 2023-05-24T12:24:30+00:00 0.5 http://www.sarepta.com/srp-9001-303-envision-study-enrollment-us 2023-06-08T16:49:15+00:00 0.5 http://www.sarepta.com/community-letter-embark-part-1-topline-results 2023-10-30T20:11:24+00:00 0.5 http://www.sarepta.com/science/investigator-initiated-studies 2024-08-28T21:07:00+00:00 0.5 http://www.sarepta.com/community-letter-update-srp-5051-program 2024-11-06T21:10:06+00:00 0.5 http://www.sarepta.com/community-letter-update-lgmd-programs-srp-9003-srp-9004-srp-9005 2024-12-19T16:13:49+00:00 0.5 http://www.sarepta.com/community-letter-elevidys-safety-update 2025-03-18T12:44:43+00:00 0.5 http://www.sarepta.com/community-letter-safety-update-regarding-elevidys-non-ambulatory-individuals-duchenne 2025-06-15T17:01:10+00:00 0.5 http://www.sarepta.com/community-letter-update-regarding-elevidys 2025-07-20T11:22:51+00:00 0.5 http://www.sarepta.com/community-letter-sarepta-therapeutics-provides-statement-shipments-elevidys 2025-07-22T00:47:05+00:00 0.5 http://www.sarepta.com/community-letter-update-shipments-gene-therapy-ambulatory-individuals-duchenne 2025-07-28T22:12:28+00:00 0.5 http://www.sarepta.com/community-letter-update-clinical-study-ultra-rare-duchenne-populations 2025-11-03T21:17:01+00:00 0.5 http://www.sarepta.com/community-letter-answering-your-questions-about-label-update-our-fda-approved-gene-therapy 2025-11-16T21:52:45+00:00 0.5 http://www.sarepta.com/community-letter-update-3-year-embark-trial-data-shows-disease-modifying-impact-our-approved-gene 2026-01-27T15:15:03+00:00 0.5 http://www.sarepta.com/community-letter-update-fda-guidance-and-plans-submit-sndas 2026-03-19T17:19:12+00:00 0.5 http://www.sarepta.com/community-letter-update-dm1-clinical-development-program 2026-03-25T12:35:33+00:00 0.5 http://www.sarepta.com/community-letter-update-fshd1-clinical-development-program 2026-03-25T12:36:31+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4 2019-08-06T22:34:28+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announce-second-quarter-2019-financial-results-and-recent-corporate 2019-08-06T22:34:28+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-0 2019-08-06T22:34:28+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-present-goldman-sachs-40th-annual-global-healthcare-conference 2019-08-06T22:34:28+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-1 2019-08-06T22:34:28+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-statement-icer-draft-evidence-report-treatments-duchenne-muscular-dystrophy 2019-08-06T22:34:28+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-first-quarter-2019-financial-results-and-recent-corporate 2019-08-06T22:34:28+00:00 0.5 http://www.sarepta.com/sarepta-announces-agreement-nationwide-childrens-hospital-rights-its-gene-therapy-program-treat 2019-08-06T22:34:28+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announce-first-quarter-2019-financial-results-and-recent-corporate 2019-08-06T22:34:28+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-2 2019-08-06T22:34:28+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-appoints-renowned-biotech-executive-john-c-martin-its-board-directors 2020-01-22T21:41:26+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-present-38th-annual-jp-morgan-healthcare-conference 2020-01-22T21:41:26+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-3 2020-01-22T21:41:26+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-partnership-roche-territories-outside-united-states-its 2020-01-22T21:41:26+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-250-million-non-dilutive-senior-secured-loan-financing 2020-01-22T21:41:26+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-fda-approval-vyondys-53tm-golodirsen-injection-treatment-duchenne 2020-01-22T21:41:26+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-4 2020-01-22T21:41:26+00:00 0.5 http://www.sarepta.com/sarepta-and-stridebio-announce-multi-target-strategic-collaboration-advance-novel-gene-therapies 2020-01-22T21:41:26+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-third-quarter-2019-financial-results-and-recent-corporate 2020-01-22T21:41:26+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-present-credit-suisse-28th-annual-healthcare-conference 2020-01-22T21:41:26+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-5 2020-02-10T15:25:11+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announce-fourth-quarter-and-full-year-2019-financial-results-and-recent 2020-02-24T15:57:47+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6 2020-02-24T15:57:47+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-present-38th-annual-jp-morgan-healthcare-conference-0 2020-02-24T15:57:47+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7 2020-03-02T18:13:02+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-third-year-route-79-duchenne-scholarship-program 2020-03-02T18:13:02+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-fourth-quarter-and-full-year-2019-financial-results-and-recent 2020-03-02T18:13:02+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8 2020-04-01T02:00:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-research-agreement-us-department-defense-evaluate-multiple 2020-04-28T14:00:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announce-first-quarter-2020-financial-results-and-recent-corporate 2020-04-29T14:00:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-9 2020-05-01T02:00:02+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-first-quarter-2020-financial-results-and-recent-corporate 2020-05-07T02:00:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-and-dyno-therapeutics-announce-agreement-develop-next-generation-gene-therapy 2020-05-11T14:00:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-present-2020-rbc-capital-markets-virtual-global-healthcare-conference 2020-05-13T02:00:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-10 2020-05-30T02:00:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-present-upcoming-investor-conferences 2020-06-03T02:00:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-share-clinical-update-srp-9003-gene-therapy-trial-treat-limb-girdle-muscular 2020-06-06T02:00:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-positive-expression-and-functional-data-srp-9003-gene-therapy-trial 2020-06-08T14:00:02+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-positive-safety-and-efficacy-data-srp-9001-micro-dystrophin-gene 2020-06-16T02:00:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-and-selecta-biosciences-enter-research-license-and-option-agreement-selectas 2020-06-18T14:00:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-and-codiak-biosciences-collaborate-research-and-develop-exosome-based 2020-06-22T14:00:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-completes-submission-new-drug-application-seeking-approval-casimersen-srp-4045 2020-06-26T14:00:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-retirement-sandy-mahatme-chief-financial-officer-and-chief-business 2020-06-30T14:00:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-11 2020-07-01T02:00:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-signs-agreement-hansa-biopharma-imlifidase 2020-07-02T14:00:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-launches-rare-lessons-program-promote-greater-diversity-and-inclusion 2020-07-15T14:00:02+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-receives-fast-track-designation-srp-9001-micro-dystrophin-gene-therapy 2020-07-24T14:00:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announce-second-quarter-2020-financial-results-and-recent-corporate 2020-07-29T14:00:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-12 2020-08-01T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-second-quarter-2020-financial-results-and-recent-corporate 2020-08-05T20:30:02+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-and-university-florida-announce-collaboration-accelerate-discovery-and 2020-08-20T13:17:16+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-fda-acceptance-casimersen-srp-4045-new-drug-application-patients 2020-08-25T20:30:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-13 2020-09-01T12:35:02+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-present-upcoming-investor-conferences-0 2020-09-04T12:35:02+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-provides-program-update-srp-9001-its-investigational-gene-therapy-treatment 2020-09-10T12:35:01+00:00 0.5 http://www.sarepta.com/long-term-functional-data-sarepta-therapeutics-most-advanced-gene-therapy-programs-be-presented 2020-09-14T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-recipients-route-79-duchenne-scholarship-program 2020-09-15T12:35:02+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-reports-sustained-functional-improvement-two-years-after-treatment-srp-9001 2020-09-28T20:30:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-investigational-gene-therapy-srp-9003-treatment-limb-girdle-muscular-dystrophy 2020-09-28T20:30:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-14 2020-10-01T12:35:01+00:00 0.5 http://www.sarepta.com/gene-therapy-company-aavantibio-launches-107-million-series-financing-perceptive-advisors-bain 2020-10-22T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announce-third-quarter-2020-financial-results-and-recent-corporate 2020-10-29T20:30:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-present-29th-annual-credit-suisse-virtual-healthcare-conference 2020-11-03T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-third-quarter-2020-financial-results-and-recent-corporate 2020-11-06T12:35:02+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-commence-dosing-next-study-commercial-process-material-srp-9001-gene-therapy 2020-11-06T12:35:02+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-named-one-boston-globes-top-places-work-2020 2020-11-20T20:30:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-present-evercore-isi-3rd-annual-healthconx-virtual-conference 2020-11-25T20:30:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-15 2020-12-01T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-share-clinical-update-srp-5051-its-investigational-ppmo-treatment-duchenne 2020-12-05T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-positive-clinical-results-momentum-phase-2-clinical-trial-srp-5051 2020-12-07T20:30:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-executive-management-changes 2020-12-14T20:30:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-16 2021-01-01T12:35:02+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-top-line-results-part-1-study-102-evaluating-srp-9001-its 2021-01-08T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-present-39th-annual-jp-morgan-healthcare-conference 2021-01-08T20:30:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-and-genevant-sciences-announce-research-collaboration-lipid-nanoparticle-based 2021-01-13T20:30:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-17 2021-01-30T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-winners-rare-lessons-lesson-planning-competition 2021-02-05T12:35:02+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announce-fourth-quarter-and-full-year-2020-financial-results-and-recent 2021-02-22T20:30:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-present-upcoming-investor-conferences-1 2021-02-25T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-fda-approval-amondys-45tm-casimersen-injection-treatment-duchenne 2021-02-25T20:30:02+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-18 2021-02-27T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-fourth-quarter-and-full-year-2020-financial-results-and-recent 2021-03-02T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-present-results-its-gene-therapy-and-rna-platforms-2021-annual-mda-clinical 2021-03-15T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-investigational-gene-therapy-srp-9003-treatment-limb-girdle-muscular-0 2021-03-19T12:35:02+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-fourth-year-route-79-duchenne-scholarship-program 2021-03-23T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-recommends-stockholders-reject-below-market-mini-tender-offer-trc-capital-investment 2021-04-26T20:30:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-statement-april-26-2021-icer-commentary-regarding-accelerated-approval-pathway 2021-04-27T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announce-first-quarter-2021-financial-results-and-recent-corporate 2021-04-28T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-share-clinical-update-30-mgkg-arm-momentum-study-srp-5051-its-investigational 2021-04-30T20:30:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-19 2021-05-01T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-reports-positive-clinical-results-phase-2-momentum-study-srp-5051-patients 2021-05-03T20:30:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-present-upcoming-investor-conferences-2 2021-05-05T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-first-quarter-2021-financial-results-and-recent-corporate 2021-05-05T20:30:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-share-expression-and-safety-results-study-103-endeavor-evaluating-srp-9001-its 2021-05-17T20:30:02+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-investigational-gene-therapy-treatment-duchenne-muscular-dystrophy-srp-9001 2021-05-18T20:30:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-20 2021-05-29T12:35:02+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-present-upcoming-investor-conferences-3 2021-06-04T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-21 2021-07-01T12:35:02+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announce-second-quarter-2021-financial-results-and-recent-corporate 2021-07-28T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-22 2021-07-31T12:35:02+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-executes-licensing-agreement-gene-therapy-program-nationwide-childrens 2021-08-04T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-second-quarter-2021-financial-results-and-recent-corporate 2021-08-04T20:30:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-23 2021-09-01T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-recipients-route-79-duchenne-scholarship-program-0 2021-09-07T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-present-upcoming-investor-conferences-4 2021-09-08T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-showcase-data-its-gene-therapy-and-rna-platforms-world-muscle-society-2021 2021-09-14T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-initiate-part-b-momentum-study-srp-5051-patients-duchenne-muscular-dystrophy 2021-09-27T12:35:02+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-24 2021-10-01T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-initiation-embark-global-pivotal-study-srp-9001-gene-therapy 2021-10-04T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-opens-genetic-therapies-center-excellence-columbus-ohio 2021-10-05T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-srp-9001-shows-sustained-functional-improvements-multiple-studies-patients 2021-10-11T20:30:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-preliminary-financial-results-third-quarter-ended-september-30-2021 2021-10-13T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-proposed-500000000-public-offering-common-stock 2021-10-12T20:30:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-pricing-500-million-public-offering-common-stock 2021-10-14T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announce-third-quarter-2021-financial-results-and-recent-corporate 2021-10-27T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-25 2021-10-30T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-present-upcoming-investor-conferences-5 2021-11-03T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-third-quarter-2021-financial-results-and-recent-corporate 2021-11-03T20:30:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-names-louise-rodino-klapac-phd-head-research-and-development 2021-11-29T23:02:22+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-appoints-stephen-l-mayo-phd-its-board-directors 2021-11-29T23:02:22+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-26 2021-12-01T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-27 2022-01-06T14:47:05+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-present-40th-annual-jp-morgan-healthcare-conference 2022-01-06T20:30:02+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-gene-therapy-srp-9001-shows-statistically-significant-functional-improvements 2022-01-10T20:30:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-28 2022-02-01T12:35:02+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-and-genedit-share-progress-research-collaboration-and-announce-agreement 2022-02-01T20:30:02+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announce-fourth-quarter-and-full-year-2021-financial-results-and-recent 2022-02-22T20:30:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-launch-sareptacircle-highlight-experiences-individuals-and-families 2022-02-23T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-anuncia-el-lanzamiento-de-sareptacircle-para-destacar-las-experiencias-de 2022-02-23T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-29 2022-03-01T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-fourth-quarter-and-full-year-2021-financial-results-and-recent 2022-03-02T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-present-upcoming-investor-conferences-6 2022-03-03T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-fifth-year-route-79-duchenne-scholarship-program 2022-03-08T20:30:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-anuncia-quinto-ano-de-route-79-el-programa-de-becas-duchenne 2022-03-08T20:30:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-30 2022-04-01T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announce-first-quarter-2022-financial-results-and-recent-corporate 2022-04-27T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-31 2022-04-30T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-present-bofa-securities-2022-healthcare-conference 2022-05-04T12:35:02+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-first-quarter-2022-financial-results-and-recent-corporate 2022-05-04T20:30:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-launches-inaugural-lgmd-grant-award-program 2022-05-05T20:30:02+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-lanza-el-programa-inaugural-de-concesion-de-subvenciones-para-la-lgmd 2022-05-10T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-32 2022-06-01T12:35:02+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-present-goldman-sachs-43rd-annual-global-healthcare-conference 2022-06-02T12:35:02+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-appoints-michael-chambers-and-kathryn-boor-phd-its-board-directors 2022-06-02T20:30:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-provides-update-srp-5051-treatment-duchenne-muscular-dystrophy 2022-06-23T20:30:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-33 2022-07-01T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-share-new-clinical-data-and-integrated-analysis-srp-9001-its-investigational 2022-07-05T20:30:02+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-investigational-gene-therapy-srp-9001-duchenne-muscular-dystrophy-demonstrates 2022-07-06T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announce-second-quarter-2022-financial-results-and-recent-corporate 2022-07-26T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-intent-submit-accelerated-approval-biologics-license-application-its 2022-07-29T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-34 2022-07-30T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-second-quarter-2022-financial-results-and-recent-corporate 2022-08-02T20:30:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-progress-myoaav-program-and-exclusive-licensing-agreement-broad 2022-08-08T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-35 2022-09-01T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-fda-has-lifted-its-clinical-hold-srp-5051-treatment-duchenne 2022-09-06T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-present-morgan-stanley-20th-annual-global-healthcare-conference 2022-09-06T20:30:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-recipients-route-79-duchenne-scholarship-program-2022-2023-academic 2022-09-07T12:35:02+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-anuncia-los-destinatarios-de-route-79-el-programa-de-becas-de-duchenne-para-el 2022-09-08T20:30:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-proposed-offering-10-billion-convertible-senior-notes-due-2027 2022-09-13T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-prices-10-billion-convertible-senior-notes-due-2027 2022-09-14T12:35:02+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-submits-biologics-license-application-srp-9001-treatment-ambulant-patients 2022-09-29T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-36 2022-10-01T12:35:02+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-presents-new-data-its-gene-therapy-and-rna-platforms-world-muscle-society-2022 2022-10-07T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announce-third-quarter-2022-financial-results 2022-10-26T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-recipients-inaugural-lgmd-grant-awards-program-supports-innovative 2022-10-26T20:30:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-anuncia-los-beneficiarios-de-la-entrega-inaugural-de-subvenciones-para-lgmd-el 2022-10-26T20:30:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-37 2022-11-01T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-third-quarter-2022-financial-results-and-recent-corporate 2022-11-02T20:30:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-present-evercore-isi-healthconx-conference 2022-11-23T20:30:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-us-fda-has-accepted-filing-and-granted-priority-review-biologics 2022-11-28T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-38 2022-12-01T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-39 2022-12-31T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-present-41st-annual-jp-morgan-healthcare-conference 2023-01-03T20:30:02+00:00 0.5 http://www.sarepta.com/sarepta-and-catalent-expand-strategic-manufacturing-partnership-commercial-supply-agreement 2023-01-05T20:30:02+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-reports-preliminary-fourth-quarter-and-full-year-2022-net-product-revenues 2023-01-09T20:30:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-40 2023-02-01T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-initiation-voyagene-clinical-study-srp-9003-treatment-limb-girdle 2023-02-17T20:30:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announce-fourth-quarter-and-full-year-2022-financial-results 2023-02-21T20:30:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-call-applications-6th-annual-route-79-duchenne-scholarship-program 2023-02-28T20:30:02+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-anuncia-convocatoria-de-solicitudes-para-el-6o-route-79-anual-el-programa-de 2023-02-28T20:30:02+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-41 2023-03-01T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-fourth-quarter-and-full-year-2022-financial-results-and-recent 2023-03-01T12:35:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-advisory-committee-meeting-will-be-held-srp-9001 2023-03-16T21:30:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-42 2023-04-01T14:10:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-date-advisory-committee-meeting-srp-9001-will-be-may-12-2023 2023-04-10T14:10:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announce-first-quarter-2023-financial-results 2023-04-25T14:10:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-43 2023-04-29T14:10:02+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-first-quarter-2023-financial-results-and-recent-corporate 2023-05-02T21:30:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-positive-vote-us-fda-advisory-committee-meeting-srp-9001-gene 2023-05-13T14:10:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-update-regulatory-review-srp-9001 2023-05-24T12:54:41+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-44 2023-06-01T14:10:02+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-fda-approval-elevidys-first-gene-therapy-treat-duchenne-muscular 2023-06-22T18:09:10+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-45 2023-07-01T14:10:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-present-cowens-2nd-annual-rna-therapeutics-summit 2023-07-03T14:10:02+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-sale-priority-review-voucher-102-million 2023-07-05T14:10:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announce-second-quarter-2023-financial-results 2023-07-26T14:10:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-46 2023-08-01T14:10:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-second-quarter-2023-financial-results-and-recent-corporate 2023-08-02T21:30:01+00:00 0.5 http://www.sarepta.com/quest-diagnostics-granted-fda-breakthrough-designation-its-adeno-associated-virus-aav-test 2023-08-30T14:10:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-47 2023-09-01T14:10:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-present-morgan-stanley-21st-annual-global-healthcare-conference 2023-09-05T14:10:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-recipients-6th-annual-route-79-duchenne-scholarship-program-2023 2023-09-07T14:10:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-anuncia-los-destinatarios-de-la-6a-edicion-anual-de-route-79-el-programa-de 2023-09-07T14:10:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-48 2023-09-30T14:10:02+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announce-third-quarter-2023-financial-results 2023-10-25T14:10:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-topline-results-embark-global-pivotal-study-elevidys-gene-therapy 2023-10-30T21:30:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-49 2023-11-01T14:10:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-third-quarter-2023-financial-results-and-recent-corporate 2023-11-01T21:30:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-present-ubs-biopharma-conference 2023-11-02T14:10:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-50 2023-12-01T14:10:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-submits-efficacy-supplement-expand-elevidys-label-include-duchenne-muscular 2023-12-22T14:10:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-51 2023-12-30T14:10:34+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-present-42nd-annual-jp-morgan-healthcare-conference 2024-01-02T14:10:58+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-reports-preliminary-fourth-quarter-and-full-year-2023-net-product-revenue 2024-01-08T21:30:47+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-initiates-screening-emergene-phase-3-clinical-study-srp-9003-treatment-limb 2024-01-16T14:10:23+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-positive-data-part-b-momentum-phase-2-study-srp-5051-patients 2024-01-29T14:10:41+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-52 2024-02-01T14:10:31+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-us-fda-acceptance-efficacy-supplement-expand-elevidys-indication 2024-02-16T14:11:55+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announce-fourth-quarter-and-full-year-2023-financial-results 2024-02-21T14:12:33+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-fourth-quarter-and-full-year-2023-financial-results-and-recent 2024-02-28T21:31:19+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-call-applications-7th-annual-route-79-duchenne-scholarship-program 2024-02-29T14:11:45+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-anuncia-convocatoria-de-solicitudes-para-el-7o-route-79-anual-el-programa-de 2024-02-29T21:34:00+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-53 2024-03-01T14:11:30+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-present-upcoming-investor-conferences-7 2024-03-04T14:11:23+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-anuncia-la-convocatoria-de-solicitudes-para-el-programa-de-concesion-de 2024-03-19T14:10:23+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-call-applications-2024-lgmd-grant-award-program 2024-03-19T14:10:23+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-54 2024-03-29T21:30:42+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announce-first-quarter-2024-financial-results 2024-04-24T14:10:37+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-55 2024-05-01T14:10:34+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-first-quarter-2024-financial-results-and-recent-corporate 2024-05-01T21:31:01+00:00 0.5 http://www.sarepta.com/gene-therapy-pioneer-jerry-r-mendell-md-named-inaugural-time100-health-list-100-most-influential 2024-05-03T14:10:25+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-56 2024-06-01T14:10:42+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-expanded-us-fda-approval-elevidys-duchenne-muscular-dystrophy 2024-06-20T21:31:13+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-57 2024-06-29T14:10:27+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announce-second-quarter-2024-financial-results 2024-07-29T14:10:47+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-58 2024-07-31T21:30:24+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-second-quarter-2024-financial-results-and-recent-corporate 2024-08-07T21:30:45+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-present-morgan-stanley-22nd-annual-global-healthcare-conference 2024-08-30T14:10:24+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-59 2024-08-30T21:30:24+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-recipients-7th-annual-route-79-duchenne-scholarship-program-2024 2024-09-05T14:10:30+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-anuncia-los-destinatarios-de-la-7a-edicion-anual-de-route-79-el-programa-de 2024-09-05T14:10:30+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-appoints-deirdre-connelly-its-board-directors 2024-09-16T14:10:46+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-present-new-data-its-neuromuscular-portfolio-2024-world-muscle-society 2024-09-26T14:10:30+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-recipients-lgmd-grant-awards-2024-program-supports-early-genetic 2024-09-30T14:10:36+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-anuncia-los-destinatarios-de-las-subvenciones-de-2024-para-lgmd-el-programa 2024-09-30T14:10:36+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-60 2024-09-30T21:31:01+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announce-third-quarter-2024-financial-results 2024-10-23T14:10:33+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-61 2024-10-31T21:30:35+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-third-quarter-2024-financial-results-and-recent-corporate 2024-11-06T21:32:03+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-global-licensing-and-collaboration-agreement-arrowhead 2024-11-26T14:05:11+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-results-part-2-embark-study-demonstrating-sustained-benefits-and 2025-01-28T16:15:52+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-reports-preliminary-fourth-quarter-and-full-year-2024-net-product-revenue 2025-01-28T16:15:52+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-present-43rd-annual-jp-morgan-healthcare-conference 2025-01-28T16:15:52+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-62 2025-01-28T16:15:52+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-completes-enrollment-emergene-phase-3-clinical-study-srp-9003-treatment-limb 2025-01-28T16:15:52+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-63 2025-01-28T16:15:52+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announce-fourth-quarter-and-full-year-2024-financial-results 2025-02-13T20:36:49+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inaugural-600-million-senior-secured-revolving-credit-facility 2025-02-15T04:00:05+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-fourth-quarter-and-full-year-2024-financial-results-and-recent 2025-02-26T21:42:36+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-call-applications-8th-annual-route-79-duchenne-scholarship-program 2025-03-01T04:00:46+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-anuncia-la-convocatoria-de-solicitudes-para-la-8a-edicion-anual-de-route-79-el 2025-03-06T21:30:05+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-shares-safety-update-elevidys 2025-03-18T13:30:05+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-64 2025-04-01T13:30:06+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-provides-update-elevidys 2025-04-04T13:30:31+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-pipeline-progress-multiple-limb-girdle-muscular-dystrophy-programs 2025-04-15T13:30:06+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announce-first-quarter-2025-financial-results 2025-04-22T13:31:04+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-first-quarter-2025-financial-results-and-recent-corporate 2025-05-06T20:30:04+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-present-bofa-securities-health-care-conference 2025-05-09T13:30:35+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-approval-japan-elevidys-gene-therapy-treat-duchenne-muscular 2025-05-13T13:30:03+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-shares-new-protein-expression-and-safety-results-endeavor-participants-2-years 2025-05-16T13:30:04+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-presents-data-american-society-gene-cell-therapy-conference-including 2025-05-16T13:30:04+00:00 0.5 http://www.sarepta.com/sarepta-provides-update-uk-dosing-envision-study-elevidys-treatment-duchenne-muscular-dystrophy 2025-05-21T13:30:04+00:00 0.5 http://www.sarepta.com/us-fda-grants-platform-technology-designation-viral-vector-used-srp-9003-sareptas-investigational 2025-06-04T20:30:04+00:00 0.5 http://www.sarepta.com/sarepta-provides-safety-update-elevidys-and-initiates-steps-strengthen-safety-non-ambulatory 2025-06-15T13:30:04+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-65 2025-07-01T13:30:04+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-strategic-restructuring-and-pipeline-prioritization-plan-maintain 2025-07-16T20:28:36+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-host-analyst-qa-regarding-lgmd-programs 2025-07-18T13:30:04+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-provides-statement-elevidys 2025-07-19T13:30:04+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-voluntary-pause-elevidys-shipments-us 2025-07-22T13:30:04+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-acknowledges-chmp-negative-opinion-elevidys-european-union 2025-07-25T13:30:29+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-provides-clarifying-statement-elevidys 2025-07-26T13:30:04+00:00 0.5 http://www.sarepta.com/fda-informs-sarepta-it-recommends-sarepta-remove-its-pause-and-resume-shipments-elevidys-ambulatory 2025-07-29T13:30:04+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announce-second-quarter-2025-financial-results 2025-07-31T13:30:12+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-second-quarter-2025-financial-results-and-recent-corporate 2025-08-06T20:30:05+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-advancement-sirna-collaboration-and-sale-arrowhead-equity-investment 2025-08-13T20:30:05+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-refinancing-approximately-700-million-125-convertible-senior-notes 2025-08-21T13:30:30+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-recipients-route-79-duchenne-scholarship-program-2025-2026-academic 2025-09-05T13:30:30+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-66 2025-10-01T13:30:04+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-present-new-data-its-neuromuscular-portfolio-2025-world-muscle-society 2025-10-03T13:30:15+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announce-third-quarter-2025-financial-results 2025-10-27T20:30:23+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-third-quarter-2025-financial-results-and-recent-corporate 2025-11-03T21:30:06+00:00 0.5 http://www.sarepta.com/sarepta-announces-fdas-approval-updated-elevidys-prescribing-information 2025-11-14T21:30:09+00:00 0.5 http://www.sarepta.com/sarepta-provides-progress-update-srp-1003-its-investigational-sirna-treatment-myotonic-dystrophy 2025-11-24T14:30:34+00:00 0.5 http://www.sarepta.com/sarepta-announces-approval-begin-endeavor-cohort-8-evaluate-enhanced-immunosuppression-regimen-part 2025-11-25T14:30:34+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-refinancing-approximately-291-million-125-convertible-senior-notes 2025-12-11T14:30:31+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-applauds-addition-duchenne-muscular-dystrophy-us-recommended-uniform-screening 2025-12-17T14:30:27+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-67 2026-01-01T14:30:19+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-present-44th-annual-jp-morgan-healthcare-conference 2026-01-05T14:30:40+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-submission-clinical-trial-application-srp-1005-its-investigational 2026-01-07T14:30:20+00:00 0.5 http://www.sarepta.com/sarepta-reports-preliminary-fourth-quarter-and-full-year-2025-net-product-revenues 2026-01-12T21:30:23+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-report-3-year-topline-data-embark-study-elevidys-gene-therapy-ambulatory 2026-01-23T21:30:21+00:00 0.5 http://www.sarepta.com/sarepta-announces-positive-topline-three-year-embark-results-showing-elevidys-significantly-slows 2026-01-26T14:30:21+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-approval-clinical-trial-application-srp-1005-its-investigational 2026-02-04T14:30:53+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announce-fourth-quarter-and-full-year-2025-financial-results 2026-02-11T14:30:29+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-commercial-launch-elevidys-japan 2026-02-24T14:30:07+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-present-td-cowen-46th-annual-health-care-conference 2026-02-24T14:30:07+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-fourth-quarter-and-full-year-2025-financial-results-and-recent 2026-02-25T21:30:10+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-present-new-long-term-and-safety-data-across-gene-therapy-and-exon-skipping 2026-02-26T14:30:08+00:00 0.5 http://www.sarepta.com/sarepta-therapeutics-announces-call-applications-9th-annual-route-79-duchenne-scholarship-program 2026-02-27T14:30:05+00:00 0.5 http://www.sarepta.com/sarepta-announces-screening-and-enrollment-are-underway-endeavor-cohort-8-evaluate-enhanced 2026-03-16T13:30:08+00:00 0.5 http://www.sarepta.com/sarepta-provides-regulatory-update-amondys-45r-and-vyondys-53r 2026-03-19T13:30:06+00:00 0.5 http://www.sarepta.com/sarepta-share-first-clinical-data-sirna-pipeline-targeting-fshd1-and-dm1 2026-03-24T20:31:04+00:00 0.5 http://www.sarepta.com/sarepta-announces-first-clinical-data-sirna-pipeline-targeting-fshd1-and-dm1 2026-03-25T13:30:12+00:00 0.5